Login to Your Account



Clinic Roundup


Friday, October 19, 2012

• Novavax Inc., of Rockville, Md., said top-line results from two Phase I trials of its A/H5N1 avian influenza vaccine candidate showed that the vaccine is safe and produces immunogenicity with and without adjuvant. It also showed statistically significant adjuvant effects on immune responses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription